英夫利西单抗在炎症性肠病治疗中的应用
摘要
炎症性肠病是一组慢性非特异性炎症性疾病,其发病机制尚不明确,控制方式主要是药物治疗。研究表明,生物制剂对IBD的治疗有非常确切的效果。IFX作为首个正式批准用于治疗IBD的生物制剂,迄今已积累了10年的临床应用经验。本文就IFX治疗炎症性肠病的作用机制、临床疗效、安全性及不良反应做一综述。
引文
[1]李玥,钱家鸣.抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)[J].协和医学杂志,2017,Z2:239-243.
[2]Hanauer SB, Feagan BG, Lichtenstein GR, et al. Mainte-nance infliximab for Crohn's disease:the ACCENT I randomised tri-al[J]. The Lancet, 2002, 359(9317):1541-1549.
[3]Kierkus J, Dadalski M, Szymanska E, et al. The impact of in-fliximab induction therapy on mucosal healing and clinical remis-sion in Polish pediatric patients with moderate-to-severe Crohn'sdisease[J]. Eur J Gastroenterol Hepatol. 2012, 24(5):495-500.
[4]Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinicaldisease activity, C-reactive protein normalisation and mucosal heal-ing in Crohn's disease in the SONIC trial[J]. Gut, 2014, 63(1):88-95.
[5]Sands BE, Anderson FH, Bernstein CN, et al. Inflix-imab maintenance therapy for fistulizing Crohn's disease[J]. N EnglJ Med. 2004,350(9):876-85.
[6]李懿璇,李世荣,李俊霞,杨欣艳,王化虹.英夫利昔单抗-类克在激素抵抗及激素依赖溃疡性结肠炎治疗中的应用[J].世界华人消化杂志,2012,21:1987-1992.
[7]Schnitzler F, Fidder H, Ferrante M, et al. Long-term out-come of treatment with infliximab in 614 patients with Crohn’s dis-ease:results from a single-centre cohort[J].Gut, 2009, 58(4):482-500.
[8]Adedokun OJ, Sandborn WJ, Feaqan BG, et al. Associationbetween serum concentration of infliximab and efficacy in adult pa-tients with ulcerative colitis[J]. Gastroenterology. 2014, 147(6):1296-1307.
[9]Cottone, Mario, Kohn, et al. Advanced Age Is an Indepen-dent Risk Factor for Severe Infections and Mortality in Patients Giv-en Anti–Tumor Necrosis Factor Therapy for Inflammatory BowelDisease[J]. Clinical Gastroenterology and Hepatology[J]. 2011,9(1):30-35.
[10]Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious in-fection and mortality in patients with Crohn’s disease:more than 5years of followup in the TREAT?registry[J]. Am J Gastroenterol,2012, 107(9):1409-1422.
[11]刘爱玲,吕红,李钥,杨红,钱家鸣.英夫利昔单抗治疗炎症性肠病95例不良反应及其危险因素分析[J].中国实用内科杂志,2018,38(3):217-222.
[2]Hanauer SB, Feagan BG, Lichtenstein GR, et al. Mainte-nance infliximab for Crohn's disease:the ACCENT I randomised tri-al[J]. The Lancet, 2002, 359(9317):1541-1549.
[3]Kierkus J, Dadalski M, Szymanska E, et al. The impact of in-fliximab induction therapy on mucosal healing and clinical remis-sion in Polish pediatric patients with moderate-to-severe Crohn'sdisease[J]. Eur J Gastroenterol Hepatol. 2012, 24(5):495-500.
[4]Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinicaldisease activity, C-reactive protein normalisation and mucosal heal-ing in Crohn's disease in the SONIC trial[J]. Gut, 2014, 63(1):88-95.
[5]Sands BE, Anderson FH, Bernstein CN, et al. Inflix-imab maintenance therapy for fistulizing Crohn's disease[J]. N EnglJ Med. 2004,350(9):876-85.
[6]李懿璇,李世荣,李俊霞,杨欣艳,王化虹.英夫利昔单抗-类克在激素抵抗及激素依赖溃疡性结肠炎治疗中的应用[J].世界华人消化杂志,2012,21:1987-1992.
[7]Schnitzler F, Fidder H, Ferrante M, et al. Long-term out-come of treatment with infliximab in 614 patients with Crohn’s dis-ease:results from a single-centre cohort[J].Gut, 2009, 58(4):482-500.
[8]Adedokun OJ, Sandborn WJ, Feaqan BG, et al. Associationbetween serum concentration of infliximab and efficacy in adult pa-tients with ulcerative colitis[J]. Gastroenterology. 2014, 147(6):1296-1307.
[9]Cottone, Mario, Kohn, et al. Advanced Age Is an Indepen-dent Risk Factor for Severe Infections and Mortality in Patients Giv-en Anti–Tumor Necrosis Factor Therapy for Inflammatory BowelDisease[J]. Clinical Gastroenterology and Hepatology[J]. 2011,9(1):30-35.
[10]Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious in-fection and mortality in patients with Crohn’s disease:more than 5years of followup in the TREAT?registry[J]. Am J Gastroenterol,2012, 107(9):1409-1422.
[11]刘爱玲,吕红,李钥,杨红,钱家鸣.英夫利昔单抗治疗炎症性肠病95例不良反应及其危险因素分析[J].中国实用内科杂志,2018,38(3):217-222.